Sol-Gel Technologies

OverviewSuggest Edit

Sol-Gel Technologies is engaged in the development of a range of specialty pharmaceuticals. The Company designs and delivers innovative dermatological drugs ranging from completely non-leachable to highly-controlled-release of unique formulations and compounds.
TypePublic
Founded1997
HQNess Ziona, IL
Websitesol-gel.com

Latest Updates

Employees (est.) (Dec 2018)56(+15%)
Share Price (Jan 2020)$14.9

Key People/Management at Sol-Gel Technologies

Moshe Arkin

Moshe Arkin

Chairman of Our Board of Directors
Alon Seri-Levy

Alon Seri-Levy

Co-Founder and Chief Executive Officer, Director
Gilad Mamlok

Gilad Mamlok

CFO
Itai Arkin

Itai Arkin

Director
Ofer Toledano

Ofer Toledano

VP Research and Development
Yaffa Krindel

Yaffa Krindel

Director
Show more

Sol-Gel Technologies Office Locations

Sol-Gel Technologies has an office in Ness Ziona
Ness Ziona, IL (HQ)
7 Golda Me'ir St
Show all (1)

Sol-Gel Technologies Financials and Metrics

Sol-Gel Technologies Revenue

Market capitalization (10-Jan-2020)

303.4m

Closing stock price (10-Jan-2020)

14.9
Sol-Gel Technologies's current market capitalization is $303.4 m.
Show all financial metrics

Sol-Gel Technologies Online and Social Media Presence

Embed Graph

Sol-Gel Technologies News and Updates

Sol-Gel Technologies Reports Third Quarter 2019 Financial Results and Corporate Update

NESS ZIONA, Israel, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced financial resul…

Sol-Gel Technologies reports positive results in trials of treatment for papulopustular rosacea

Sol-Gel Technologies Ltd. said Monday that two late-stage trials of a treatment for papulopustular rosacea produced positive results. The Israeli company said the trials evaluating Epsolay(R) microencapsulated benzoyl peroxide cream, 5%, made with the company's proprietary microencapsulation techno…

Sol-Gel Technologies Reports First Quarter 2019 Financial Results and Corporate Update

Top-line results from Phase III Epsolay® and TWIN trials remain on track; mid-2019 and 4Q19, respectfully

Sol-Gel Technologies Announces 50% Enrollment in Pivotal Phase III TWIN Program for the Treatment of Acne Vulgaris

Patient enrollment of the pivotal Phase III TWIN clinical trials is on schedule

Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update

Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay® and TWIN, potentially best-in-class papulopustular rosacea and acne vulgaris topical medications

Sol-Gel Technologies Announces FDA Approval for Perrigo’s Generic Acyclovir Cream, 5%

Sol-Gel and Perrigo will equally share the gross profits generated from sales of the product Sol-Gel and Perrigo will equally share the gross profits generated from sales of the product
Show more

Sol-Gel Technologies Blogs

Sol-Gel Hosts Investor Call to Discuss Positive Results from Twyneo® Phase 3 Program in Acne Vulgaris

Conference call with Sol-Gel management and U.S. key opinion leader today at 8:00 a.m. Eastern time NESS ZIONA, Israel , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will host a conference call today to discuss results from two Phase 3 clinical trials for Twyneo®, an

Sol-Gel Technologies Reports Second Quarter 2019 Financial Results and Corporate Update

Top-line generic product revenue of $7.8 million TWIN Phase 3 trials are fully enrolled and remain on track to report results in 4Q19 NESS ZIONA, Israel , Aug. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying,

Sol-Gel Announces Pricing of Public Offering of Ordinary Shares

NESS ZIONA, Israel , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel” or the “Company”),  a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases,

Sol-Gel Technologies Hosting Analyst & Investor Day

Sol-Gel Technologies Hosting Analyst & Investor Day Content Import Thu, 07/25/2019 - 06:01 Sol-Gel Technologies Hosting Analyst & Investor Day July 25, 2019 at 6:00 AM EDT This release is a backfill from a News Wire General …

Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea

Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea Content Import Mon, 07/08/2019 - 07:06 Sol-Gel Announces Positive Top-Line Results from Epsolay® Phase 3 Program in Papulopustular Rosacea July 8, 2019 at 7:05 AM EDT …

Sol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019

Sol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019 Content Import Mon, 06/17/2019 - 07:01 Sol-Gel Technologies to Host Analyst & Investor Day on July 25, 2019 June 17, 2019 at 7:00 AM EDT This release is a backfill from a News Wire …

Sol-Gel Technologies Frequently Asked Questions

  • When was Sol-Gel Technologies founded?

    Sol-Gel Technologies was founded in 1997.

  • Who are Sol-Gel Technologies key executives?

    Sol-Gel Technologies's key executives are Moshe Arkin, Alon Seri-Levy and Gilad Mamlok.

  • How many employees does Sol-Gel Technologies have?

    Sol-Gel Technologies has 56 employees.

  • Who are Sol-Gel Technologies competitors?

    Competitors of Sol-Gel Technologies include Faes Farma, AbbVie and SciClone Pharmaceuticals.

  • Where is Sol-Gel Technologies headquarters?

    Sol-Gel Technologies headquarters is located at 7 Golda Me'ir St, Ness Ziona.

  • Where are Sol-Gel Technologies offices?

    Sol-Gel Technologies has an office in Ness Ziona.

  • How many offices does Sol-Gel Technologies have?

    Sol-Gel Technologies has 1 office.